NZ760233A - Compositions and methods for treatment of abnormal cell growth - Google Patents

Compositions and methods for treatment of abnormal cell growth

Info

Publication number
NZ760233A
NZ760233A NZ760233A NZ76023315A NZ760233A NZ 760233 A NZ760233 A NZ 760233A NZ 760233 A NZ760233 A NZ 760233A NZ 76023315 A NZ76023315 A NZ 76023315A NZ 760233 A NZ760233 A NZ 760233A
Authority
NZ
New Zealand
Prior art keywords
composition
pharmaceutically acceptable
acceptable salt
tablet
pharmaceutical composition
Prior art date
Application number
NZ760233A
Other languages
English (en)
Inventor
Mahesh Padval
Paul Nkansah
Original Assignee
Pfizer
Verastem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Verastem Inc filed Critical Pfizer
Publication of NZ760233A publication Critical patent/NZ760233A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
NZ760233A 2014-01-09 2015-01-09 Compositions and methods for treatment of abnormal cell growth NZ760233A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461925467P 2014-01-09 2014-01-09
NZ721934A NZ721934A (en) 2014-01-09 2015-01-09 Compositions and methods for treatment of abnormal cell growth

Publications (1)

Publication Number Publication Date
NZ760233A true NZ760233A (en) 2022-04-29

Family

ID=52434976

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ760233A NZ760233A (en) 2014-01-09 2015-01-09 Compositions and methods for treatment of abnormal cell growth
NZ721934A NZ721934A (en) 2014-01-09 2015-01-09 Compositions and methods for treatment of abnormal cell growth

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ721934A NZ721934A (en) 2014-01-09 2015-01-09 Compositions and methods for treatment of abnormal cell growth

Country Status (15)

Country Link
US (3) US20150190346A1 (https=)
EP (2) EP3091981B1 (https=)
JP (5) JP6647204B2 (https=)
KR (3) KR102444494B1 (https=)
CN (3) CN115708827A (https=)
AU (4) AU2015204597B2 (https=)
BR (1) BR112016016021B1 (https=)
CA (1) CA2936283C (https=)
DK (1) DK3091981T3 (https=)
ES (1) ES2870562T3 (https=)
IL (2) IL246667B (https=)
MX (2) MX384259B (https=)
NZ (2) NZ760233A (https=)
SG (2) SG11201605588YA (https=)
WO (1) WO2015106096A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102942294B1 (ko) * 2018-05-15 2026-03-23 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 소분자 이지에프알 억제제를 포함하는 약학 조성물 및 그의 제조 방법
JP2022547358A (ja) 2019-09-13 2022-11-14 ジ インスティテュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル 治療組成物、組み合わせ、及び使用方法
JP2021155415A (ja) * 2020-03-27 2021-10-07 ファイザー・インク ２−［（４−｛６−［（４−シアノ−２−フルオロベンジル）オキシ］ピリジン−２−イル｝ピペリジン−１−イル）メチル］−１−［（２ｓ）−オキセタン−２−イルメチル］−１ｈ−ベンゾイミダゾール−６−カルボン酸またはその薬学的な塩を用いた２型糖尿病、または肥満、または過体重の治療
MX2022013344A (es) * 2020-04-24 2022-11-30 Dr Falk Pharma Gmbh Formulacion sistemica de un derivado de la piridinona para las enfermedades relacionadas con la tg2.
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
WO2024037498A1 (zh) * 2022-08-15 2024-02-22 海创药业股份有限公司 一种治疗卵巢癌的联合用药物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2287971T3 (es) * 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
BRPI0413363A (pt) * 2003-08-04 2006-10-10 Pfizer Prod Inc formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase
WO2006061712A2 (en) * 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
CN101678215B (zh) * 2007-04-18 2014-10-01 辉瑞产品公司 用于治疗异常细胞生长的磺酰胺衍生物
HRP20180328T1 (hr) * 2008-08-13 2018-04-20 Vertex Pharmaceuticals Inc. FARMACEUTSKI PRIPRAVAK N-[2,4-bis(1,1-DIMETILETIL)-5-HIDROKSIFENIL]-1,4-DIHIDRO-4-OKSOKINOLIN-3-KARBOKSAMIDA I NJEGOVO DAVANJE
WO2011112922A2 (en) * 2010-03-11 2011-09-15 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
CA2808501A1 (en) * 2010-08-23 2012-03-01 Vertex Pharmaceuticals Incorporated Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
US8591944B2 (en) * 2011-03-08 2013-11-26 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
EP2572731A1 (en) * 2011-09-26 2013-03-27 Abbott GmbH & Co. KG Formulations based on solid dispersions
WO2015120289A1 (en) * 2014-02-07 2015-08-13 Verastem, Inc. Methods and compositions for treating abnormal cell growth
US10532056B2 (en) * 2015-06-29 2020-01-14 Verastem, Inc. Therapeutic compositions, combinations, and methods of use

Also Published As

Publication number Publication date
US20200038331A1 (en) 2020-02-06
NZ721934A (en) 2022-04-29
AU2025204843A1 (en) 2025-07-17
AU2015204597A1 (en) 2016-07-21
CA2936283A1 (en) 2015-07-16
MX2016009056A (es) 2017-01-23
AU2020210153A1 (en) 2020-08-13
JP2017502062A (ja) 2017-01-19
IL246667B (en) 2022-05-01
US20150190346A1 (en) 2015-07-09
CN115708827A (zh) 2023-02-24
MX2021008225A (es) 2021-08-11
AU2015204597B2 (en) 2020-04-30
IL246667A0 (en) 2016-08-31
BR112016016021A8 (pt) 2018-04-17
JP2025084892A (ja) 2025-06-03
MX384259B (es) 2025-03-14
AU2022256144B2 (en) 2025-04-03
AU2022256144A1 (en) 2022-11-24
DK3091981T3 (da) 2021-05-31
CA2936283C (en) 2023-02-28
SG10201805890QA (en) 2018-08-30
BR112016016021B1 (pt) 2023-01-10
KR20220130251A (ko) 2022-09-26
SG11201605588YA (en) 2016-08-30
CN119868364A (zh) 2025-04-25
CN106102744A (zh) 2016-11-09
AU2020210153B2 (en) 2022-07-21
KR20240159639A (ko) 2024-11-05
EP3900726A1 (en) 2021-10-27
BR112016016021A2 (pt) 2017-09-19
ES2870562T3 (es) 2021-10-27
IL292054A (en) 2022-06-01
JP6647204B2 (ja) 2020-02-14
WO2015106096A1 (en) 2015-07-16
KR20160104725A (ko) 2016-09-05
JP2020007355A (ja) 2020-01-16
US20230104303A1 (en) 2023-04-06
JP2023065568A (ja) 2023-05-12
KR102444494B1 (ko) 2022-09-20
JP2022001587A (ja) 2022-01-06
EP3091981B1 (en) 2021-03-10
EP3091981A1 (en) 2016-11-16

Similar Documents

Publication Publication Date Title
JP7627302B2 (ja) パルボシクリブの固形剤形
AU2022256144B2 (en) Compositions and methods for treatment of abnormal cell growth
CN102085201B (zh) 阿替洛尔和氨氯地平的双层片剂
EP2974720A1 (en) Mosapride sustained-release preparation for providing pharmacological clinical effects with once-a-day administration
MXPA04010496A (es) Tableta con alta carga de farmaco.
KR20160000762A (ko) 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 및 그 제조방법
CN102711761B (zh) 溶出稳定化制剂
CN115835859A (zh) 包括西他列汀和达格列净的复合制剂以及其制备方法
HK40062771A (en) Compositions and methods for treatment of abnormal cell growth
CN104147012B (zh) 一种含有替加氟、吉莫斯特和奥替拉西钾的口腔崩解制剂
HK1230956B (en) Compositions and methods for treatment of abnormal cell growth
KR20260022394A (ko) 에스트로겐 수용체 분해제의 고형 경구제
TW202432128A (zh) （Ｒ）－１－（１－丙烯醯基哌啶－３－基）－４－胺基－３－（４－苯氧基苯基）－１Ｈ－咪唑並［４，５－ｃ］吡啶－２（３Ｈ）－酮之藥品調配物
HK1230942A1 (en) Compositions and methods for treatment of abnormal cell growth
CN119365195A (zh) 含有匹米替比的医药组合物

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JAN 2024 BY COMPUTER PACKAGES INC

Effective date: 20230117

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JAN 2025 BY COMPUTER PACKAGES INC

Effective date: 20240317

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JAN 2026 BY COMPUTER PACKAGES INC

Effective date: 20241217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JAN 2027 BY COMPUTER PACKAGES INC

Effective date: 20251217